Clinical trial NCT01495208: Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Official title: This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Fibrovascular Pigment Epithelial Detachment
Lead sponsor: Vitreous -Retina- Macula Consultants of New York
Sponsor class: OTHER
Collaborators: name: Regeneron Pharmaceuticals
First posted: 2011-12-19
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label study to evaluate the efficacy of intravitreal aflibercept injection 2mg in patients with a persistent FVPED despite at least 6 consecutive injections with ranibizumab 0.5 mg.

Detailed description: This is an open label study to evaluate the efficacy of intravitreal aflibercept injection 2mg in patients with a persistent FVPED despite at least 6 consecutive injections with ranibizumab 0.5 mg.

Patients being evaluated at VRM New York with neovascular AMD who have persistent sub-foveal FVPED on OCT despite at least 6 consecutive ranibizumab injections will be considered for the study.

We aim to recruit 25 patients in the study. There have been no statistical tests to calculate sample size; sample size of 25 patients is chosen, making sure that it is feasible financially to conduct the study and logistically to complete the study within 24 weeks. This is a pilot study to assess the effects of intravitreal aflibercept injection on chronic, persistent FVPEDs; currently there is no data regarding visual and anatomical outcomes for this group of patients.

Patients will be reviewed at baseline and then at 4 week intervals (28 ± 7 days). They will receive intravitreal intravitreal aflibercept injection 2mg at each visit. The primary end point of the study is 24 weeks from baseline. Patients who complete the study will have received 6 injections of intravitreal aflibercept injection 2mg.

Eligibility criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study
* Age \> 50 years
* Subfoveal FVPED assessed using clinical examination and OCT
* Best corrected visual acuity in the study eye between 20 and 85 letters on the ETDRS chart (20/30 to 20/800 Snellen equivalent)
* Prior treatment with at least 6 consecutive injections with ranibizumab 0.5 mg prior to the baseline visit; the last treatment with ranibizumab should not exceed 45 days from the baseline visit.

Exclusion Criteria:

* Pregnancy (positive pregnancy test) or lactation
* Participation in another simultaneous medical investigation or trial
* Prior treatment with ranibizumab therapy in the study eye within 30 days of baseline
* Prior treatment with PDT in the study eye
* Prior intravitreal injection of a corticosteroid (triamcinolone, dexamethasone) within 120 days from baseline.
* Presence of significant subfoveal fibrosis or atrophy determined using SDOCT, fluorescein angiography and clinical examination.
* Presence of fibrous or fibrocellular material occupying more than 50% of the sub-RPE space; assessed using EDI OCT
* Presence of a RPE tear, determined by clinical examination, FA, FAF and OCT
* Intraocular surgery (including cataract surgery) in the study eye within 90 days preceding baseline
* History of pars plana vitrectomy, submacular surgery or any other surgical intervention for vitreo-retinal diseases in the study eye
* Presence of or previous history of diabetic macular edema or proliferative diabetic retinopathy.
* History of uveitis in the study eye
* Current vitreous hemorrhage in the study eye
* History of rhegmatogenous retinal detachment, macular hole and lamellar hole and in the study eye
* Ocular or periocular infection
* Active severe intraocular inflammation
* Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication)
* In patients with glaucoma, advanced field loss; mean deviation on threshold visual field of more than 12 decibels.
* History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.
* History of allergy to fluorescein, ICG or iodine, not amenable to treatment
* Known hypersensitivity to aflibercept or to any of the excipients

Primary outcomes:
measure: Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany)
timeFrame: 24 weeks is the primary end point of the study
measure: Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany)
timeFrame: 24 weeks is the primary end point of the study
measure: Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany)
timeFrame: 24 weeks is the primary end point of the study
measure: Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany)
timeFrame: 24 weeks is the primary end point of the study
Secondary outcomes:
measure: Mean change in best corrected visual acuity (BCVA) from baseline; measured by ETDRS visual refraction at 4 meters.
timeFrame: 24 weeks is the primary end point of the study
measure: Mean change in best corrected visual acuity (BCVA) from baseline; measured by ETDRS
timeFrame: 24 weeks is the primary end point of the study
Other outcomes:
Locations:
city: New York
country: United States
facility: Vitreous Retina Macula Consultants of New York
state: New York
Study officials:
affiliation: Vitreous -Retina- Macula Consultants of New York
name: Richard Spaide, MD
role: PRINCIPAL_INVESTIGATOR
References: